Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin’s lymphoma

Machover, D.; Delmas-Marsalet, Béatrice; Misra, Srimanta Chandra; Gümüş, Yusuf Yasin; Goldschmidt, Emma; Schilf, A.; Frenoy, N.; Émile, Jean-François; Debuire, Brigitte; Guettier, Catherine; Farrokhi, Pegah; Boulefdaoui, B.; Norol, Françoise; Parquet, Nathalie; Ulusakarya, Ayhan; Jasmin, C

doi:10.1023/a:1012501305214

Cited by 42 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such a regimen has previously proved to be effective in aggressive lymphoma in relapse. [80][81][82] Our observation should encourage the use of such a potentially synergistic combination in patients with HS␥␦TCL.…”

Section: Discussionmentioning

confidence: 73%

Hepatosplenic T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

Belhadj

Reyes²,

Farcet³

et al. 2003

Blood

407

399

View full text Add to dashboard Cite

We report on the characteristics of 21 patients with hepatosplenic ␥␦ T-cell lymphoma (HS␥␦TCL), an entity recognized since 1994 in the Revised European American Lymphoma (REAL) classification. Median age was 34 years. Patients had splenomegaly (n ‫؍‬ 21), hepatomegaly (n ‫؍‬ 15), and thrombocytopenia (n ‫؍‬ 20). Histopathologic findings were homogeneous and showed the presence of medium-sized lymphoma cells within the sinusoids of splenic red pulp, liver, and bone marrow. Marrow involvement was usually mild but could be demonstrated by phenotyping in all patients. Cells were CD3 ؉ CD5 ؊ , expressed the ␥␦ T-cell receptor, and had a nonactivated cytotoxic cell phenotype (TIA-1 ؉ ,

show abstract

Section: Discussionmentioning

confidence: 73%

Hepatosplenic T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

Belhadj

Reyes²,

Farcet³

et al. 2003

Blood

407

399

View full text Add to dashboard Cite

show abstract

“…The dexamethasone, cytarabine and oxaliplatin (DHAOx or DHAX) regimen has been assessed by three different study groups, demonstrating response rates of 50% to 73% in patients with advanced lymphoma. [12][13][14] Treatment was associated with frequent (66% -75%) but manageable grade 3/4 hematologic toxicity. The lack of renal toxicity observed with oxaliplatin-containing regimens is particularly advantageous when treatment is considered in heavily pretreated patients or in elderly patients with comorbidities.…”

Section: Discussionmentioning

confidence: 99%

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

Gnaoui²,

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The rationale for developing the OFAR regimen was threefold: (i) preclinical data had shown synergistic cytotoxicity between oxaliplatin and the nucleoside analogues cytarabine and fludarabine [72,73]; (ii) the administration of fludarabine before cytarabine increases the intracellular concentration of the active metabolite, that is cytarabine triphosphate [73] and (iii) oxaliplatin-based regimens containing high dose cytarabine have shown activity in relapsed de novo DLBCL as well as other lymphoma types [74,75]. Fifty per cent of RS patients attained a complete response or a partial response with the OFAR regimen [71].…”

Section: Treatment Of Richter Syndromementioning

confidence: 99%

Richter syndrome: molecular insights and clinical perspectives

Rossi

Gaïdano

2009

Hematological Oncology

108

View full text Add to dashboard Cite

Richter syndrome (RS) represents the clinico-pathologic transformation of chronic lymphocytic leukaemia (CLL) to an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). The clinical definition of RS is heterogeneous, and encompasses at least two biologically different conditions: (i) CLL transformation to a clonally related DLBCL, that accounts for the majority of cases; (ii) development of a DLBCL unrelated to the CLL clone. In clonally related RS, the pathogenetic link between the CLL and the DLBCL phases is substantiated by the acquisition of novel molecular lesions at the time of clinico-pathologic transformation. RS is not a rare event in the natural history of CLL, since the cumulative incidence of RS at 10 years exceeds 10%. Prompt recognition of RS is known to be clinically useful, and may be favoured by close monitoring of CLL patients harbouring clinical and/or biological risk factors of RS development. Conventional risk factors that are independent predictors of RS development at the time of CLL diagnosis include: (i) expression of CD38; (ii) absence of del13q14 and (iii) lymph node size 3 cm. Other risk factors of RS development include CD38 genotype and usage of specific immunoglobulin variable genes. The molecular pathogenesis of RS has been elucidated to a certain extent. Acquisition of TP53 mutations and/or 17p13 deletion is a frequent molecular event in RS, as it is in other types of transformation from indolent to aggressive B-cell malignancies. Additional molecular alterations are being revealed by genome wide studies. Once that transformation has occurred, RS prognosis may be predicted by the RS score, based on performance status, LDH, platelet count, tumour size and number of prior therapies. Depending on patient's age and RS score, the therapeutic options for RS may range from conventional immunochemotherapy to allogeneic bone marrow transplantation.

show abstract

Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin’s lymphoma

Abstract: DHAOx possesses characteristics of toxicity which compare favorably to those reported with DHAP, and it is useful as a salvage treatment for patients with NHL. Larger studies are required to establish the therapeutic potential of the regimen.

Cited by 42 publications

References 14 publications

Hepatosplenic T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

Hepatosplenic T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

Richter syndrome: molecular insights and clinical perspectives

Contact Info

Product

Resources

About